Clinical trial
A Phase 3, Open Label Responder Treatment Period With a Randomized, Blinded, Three-Period Crossover, Followed by an Open Label Safety Period to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Investigational Drug MP-101 (Opium Tincture and Opium Tincture With Reduced Uncharacterized Material) to Treat Chronic Diarrhea in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals
NCT02242656 is registered in ClinicalTrials.gov with Marathon Pharmaceuticals, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Open Label Responder Treatment Period With a Randomized, Blinded, Three-Period Crossover, Followed by an Open Label Safety Period to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Investigational Drug MP-101 (Opium Tincture and Opium Tincture With Reduced Uncharacterized Material) to Treat Chronic Diarrhea in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals
- Lead sponsor
- Marathon Pharmaceuticals, LLC
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- December 31, 2014
- Completion date
- Not reported
- Enrollment
- 0 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
sbs, short bowel, short bowel syndrome, short gut, short gut syndrome